{"id":50305,"title":"Study Procedures (Part 6 of Safety and Efficacy of Imatinib for Preserving Beta-Cell Function in New-onset Type 1 Diabetes Mellitus)","title_html":"<p>Study Procedures (Part 6 of Safety and Efficacy of Imatinib for Preserving Beta-Cell Function in New-onset Type 1 Diabetes Mellitus)<\/p>","image":{"source":"https:\/\/www.protocols.io\/img\/default_protocol.png","placeholder":"https:\/\/www.protocols.io\/img\/default_protocol.png"},"doi":"dx.doi.org\/10.17504\/protocols.io.bvc9n2z6","doi_status":2,"uri":"study-procedures-part-6-of-safety-and-efficacy-of-bvc9n2z6","type_id":1,"template_id":1,"published_on":1623449406,"parent_protocols":[],"parent_collections":[],"cited_protocols":[],"version_id":0,"version_data":{"id":"0","code":"bvc9n2z6","parent_id":0,"parent_uri":null,"is_same_owner":false,"has_pending_merge_request":false,"has_approved_merge_request":false},"created_on":1622218176,"modified_on":null,"categories":null,"public":1,"is_unlisted":0,"creator":{"name":"Stephen.Gitelman ","affiliation":null,"affiliations":[],"username":"m4wle1y1v1w4tle1","note":null,"link":null,"image":{"source":"\/img\/avatars\/002.png","placeholder":"\/img\/avatars\/002.png"},"badges":[{"id":4,"image":{"source":"\/img\/badges\/gold.svg","placeholder":"\/img\/badges\/gold.svg"},"name":"Gold power author!"}],"verified":0,"is_verified_user":false,"research_interests":null,"blocked_by_you":false,"blocked_you":false,"hide_following":false},"journal":null,"journal_name":null,"journal_link":null,"article_citation":null,"has_versions":0,"link":null,"total_collections":1,"number_of_steps":7,"authors":[{"name":"Stephen.Gitelman ","affiliation":"Professor of Clinical Pediatrics, Department of Pediatrics University of California, San Francisco Room S-679, Campus Box 0434, 513 Parnassus Avenue, San Francisco, CA 94143","affiliations":[],"username":"m4wle1y1v1w4tle1","note":"","link":null,"image":{"source":"\/img\/avatars\/002.png","placeholder":"\/img\/avatars\/002.png"},"badges":[],"verified":1,"is_verified_user":true,"research_interests":null,"blocked_by_you":false,"blocked_you":false,"hide_following":false},{"name":"Jeffrey A. Bluestone","affiliation":"Professor of Medicine, Pathology, Microbiology & Immunology, University of California, San Francisco, Campus Box 0540, 513 Parnassus Avenue San Francisco, CA 94143","affiliations":[],"username":null,"note":"","link":null,"image":{"source":null,"placeholder":null},"badges":[],"verified":0,"is_verified_user":false,"research_interests":null,"blocked_by_you":false,"blocked_you":false,"hide_following":false}],"versions":[],"groups":[{"id":25652,"uri":"gitelman-ucsf","title":"Gitelman UCSF","image":{"source":"https:\/\/www.protocols.io\/img\/group_placeholder.png","placeholder":"https:\/\/www.protocols.io\/img\/group_placeholder.png"},"tech_support":{"email":null,"phone":null,"hide_contact":0,"use_email":0,"url":null},"is_member":1,"request":{"id":25652,"uri":"gitelman-ucsf","title":"Gitelman UCSF","image":{"source":"https:\/\/www.protocols.io\/img\/group_placeholder.png","placeholder":"https:\/\/www.protocols.io\/img\/group_placeholder.png"},"tech_support":{"email":null,"phone":null,"hide_contact":0,"use_email":0,"url":null},"is_member":1,"description":null,"research_interests":null,"website":null,"location":null,"affiliation":null,"status":{"is_visible":true,"access_level":0},"stats":{"files":[],"total_members":0,"total_followers":0,"total_child_groups":0,"total_parent_groups":0,"has_collaborations":0},"user_status":{"is_member":true,"is_confirmed":true,"is_invited":false,"is_owner":true,"is_admin":false,"is_following":false},"join_link":null,"token":null,"owner":{"name":" ","affiliation":null,"affiliations":[],"username":null,"note":null,"link":null,"image":{"source":null,"placeholder":null},"badges":[],"verified":0,"is_verified_user":false,"research_interests":null,"blocked_by_you":false,"blocked_you":false,"hide_following":false},"is_protocol_requested":0,"is_group_requested":0,"is_my":false,"is_request":false,"is_confirmed":1,"is_declined":0,"requester":{"name":" ","affiliation":null,"affiliation_url":null,"username":null,"link":null},"protocol":{"id":0,"title":"Study Procedures (Part 6 of Safety and Efficacy of Imatinib for Preserving Beta-Cell Function in New-onset Type 1 Diabetes Mellitus)","title_html":"Study Procedures (Part 6 of Safety and Efficacy of Imatinib for Preserving Beta-Cell Function in New-onset Type 1 Diabetes Mellitus)","image":{"source":null,"placeholder":null},"doi":null,"doi_status":0,"uri":"study-procedures-part-6-of-safety-and-efficacy-of-bvc9n2z6","type_id":1,"template_id":0,"published_on":null,"stats":{"number_of_views":0,"number_of_steps":0,"number_of_bookmarks":0,"number_of_comments":0,"number_of_exports":0,"number_of_runs":0,"number_of_votes":0,"is_voted":0},"parent_protocols":[],"parent_collections":[],"cited_protocols":[]},"created_on":1623449409,"resolve_on":0,"resolved_user":{"name":" ","affiliation":null,"affiliations":[],"username":null,"note":null,"link":null,"image":{"source":null,"placeholder":null},"badges":[],"verified":0,"is_verified_user":false,"research_interests":null,"blocked_by_you":false,"blocked_you":false,"hide_following":false},"shared":false}}],"is_owner":1,"has_subprotocols":0,"is_subprotocol":0,"is_bookmarked":0,"can_claim_authorship":0,"can_accept_authorship":0,"can_be_copied":1,"can_remove_fork":1,"fork_id":null,"url":"https:\/\/www.protocols.io\/view\/study-procedures-part-6-of-safety-and-efficacy-of-bvc9n2z6","forks_count":{"private":0,"public":0},"access":{"can_view":1,"can_remove":0,"can_add":0,"can_edit":0,"can_publish":0,"can_get_doi":0,"can_share":1,"can_move":1,"can_move_outside":1,"can_transfer":1,"can_download":1,"is_locked":0},"guid":"58B88CF0BFCE11EB96916DAEC372AC2B","state_version_id":133,"steps":[{"id":1188241,"guid":"54BEA5C0C04C11EB9E99D1E1A580FFCD","previous_id":null,"previous_guid":null,"modified_on":0,"protocol_id":0,"components":[{"id":1054723,"guid":"35A429A1AE2F40F69420EFF50E2DD285","order_id":1,"type_id":6,"title":"Section","source":{"title":"Random Assignment"}},{"id":1054724,"guid":"FE47FC2C2DCA44FD9DD5338390EDAFE2","order_id":1,"type_id":1,"title":"description","source":{"description":"<div class = \"text-blocks\"><div class = \"text-block\">Participants who sign the informed consent and meet the eligibility criteria will be randomly assigned in a 2:1 ratio to either the experimental or control group. A central automated randomization system will be used for treatment assignment and to create a unique identifier for each new study participant. Random assignment will be stratified according to site.<\/div><\/div>"}}],"cases":[],"data":null,"html":null,"section":null,"section_color":"#A492FF","section_duration":0,"critical":null,"critical_id":null,"duration":0},{"id":1188242,"guid":"67B82160C04C11EB9E99D1E1A580FFCD","previous_id":1188241,"previous_guid":"54BEA5C0C04C11EB9E99D1E1A580FFCD","modified_on":0,"protocol_id":0,"components":[{"id":1054723,"guid":"7A85751B60B749D9B2B3627418C7873E","order_id":1,"type_id":6,"title":"Section","source":{"title":"Blinding"}},{"id":1054724,"guid":"C1A7A78D541646A1B673025D38CDBE86","order_id":1,"type_id":1,"title":"description","source":{"description":"<div class = \"text-blocks\"><div class = \"text-block\">Blinding will be maintained throughout the study for all study participants and study personnel, except the pharmacists.<\/div><\/div>"}}],"cases":[],"data":null,"html":null,"section":null,"section_color":"#94EBFF","section_duration":0,"critical":null,"critical_id":null,"duration":0},{"id":1188243,"guid":"753CF9F0C04C11EB9E99D1E1A580FFCD","previous_id":1188242,"previous_guid":"67B82160C04C11EB9E99D1E1A580FFCD","modified_on":0,"protocol_id":0,"components":[{"id":1054723,"guid":"1CEB9A89916B4BA3A1427D5C236A723F","order_id":1,"type_id":6,"title":"Section","source":{"title":"Unblinding"}},{"id":1054724,"guid":"FF75A83A7D3E498FA7CD0C1B229365D6","order_id":1,"type_id":1,"title":"description","source":{"description":"<div class = \"text-blocks\"><div class = \"text-block\">Unblinding before the study is completed will occur only if a participant\u2019s well-being is threatened and the investigator believes unblinding is necessary to protect the participant.<\/div><\/div>"}}],"cases":[],"data":null,"html":null,"section":null,"section_color":"#84CE84","section_duration":0,"critical":null,"critical_id":null,"duration":0},{"id":1188244,"guid":"88C261E0C04C11EB9E99D1E1A580FFCD","previous_id":1188243,"previous_guid":"753CF9F0C04C11EB9E99D1E1A580FFCD","modified_on":0,"protocol_id":0,"components":[{"id":1054723,"guid":"AD91E26C2CA44419887963215B3E41DF","order_id":1,"type_id":6,"title":"Section","source":{"title":"Unblinding"}},{"id":1054724,"guid":"4BD6621F16934AC5A8CD779CF6AC2F44","order_id":1,"type_id":1,"title":"description","source":{"description":"<div class = \"text-blocks\"><div class = \"text-block\">Before treatment assignment for an individual participant is unblinded, the investigator must confer with the study sponsor and the medical monitor. The site investigator will notify the protocol chairs of the unblinding event, and the medical monitor will notify the study management team (SMT).<\/div><\/div>"}}],"cases":[],"data":null,"html":null,"section":null,"section_color":"#84CE84","section_duration":0,"critical":null,"critical_id":null,"duration":0},{"id":1188245,"guid":"8FBFA0C0C04C11EB9E99D1E1A580FFCD","previous_id":1188244,"previous_guid":"88C261E0C04C11EB9E99D1E1A580FFCD","modified_on":0,"protocol_id":0,"components":[{"id":1054723,"guid":"30484AE8766846E1A4CCC03F62A6F495","order_id":1,"type_id":6,"title":"Section","source":{"title":"Unblinding"}},{"id":1054724,"guid":"2FF5D65D1285446D97E6C1BE51C275E1","order_id":1,"type_id":1,"title":"description","source":{"description":"<div class = \"text-blocks\"><div class = \"text-block\">The emergency unblinding will be recorded and reported to the DSMB. A full account of the event will be recorded, including the date and time of the emergency, the reason for the decision to unblind, and the names of the medical monitor and others who were notified of the emergency. During site visits, the site monitor must verify that the medical monitor was notified and that a written account was completed. The reasons for unblinding of a participant\u2019s treatment will be included in the final study report.<\/div><\/div>"}}],"cases":[],"data":null,"html":null,"section":null,"section_color":"#84CE84","section_duration":0,"critical":null,"critical_id":null,"duration":0},{"id":1188246,"guid":"95570E10C04C11EB9E99D1E1A580FFCD","previous_id":1188245,"previous_guid":"8FBFA0C0C04C11EB9E99D1E1A580FFCD","modified_on":0,"protocol_id":0,"components":[{"id":1054723,"guid":"2531A51BAD624EBAB37EA0FD5657F8C2","order_id":1,"type_id":6,"title":"Section","source":{"title":"Unblinding"}},{"id":1054724,"guid":"6116870A125E43798421CC8334256CF7","order_id":1,"type_id":1,"title":"description","source":{"description":"<div class = \"text-blocks\"><div class = \"text-block\">Sponsor approval is required for unblinding the treatment of an individual participant or subgroups of participants for unplanned interim analyses to support DSMB reviews and final analysis.<\/div><\/div>"}}],"cases":[],"data":null,"html":null,"section":null,"section_color":"#84CE84","section_duration":0,"critical":null,"critical_id":null,"duration":0},{"id":1188247,"guid":"9D77BE50C04C11EB9E99D1E1A580FFCD","previous_id":1188246,"previous_guid":"95570E10C04C11EB9E99D1E1A580FFCD","modified_on":0,"protocol_id":0,"components":[{"id":1054723,"guid":"45098F41D45A4199A4E4AA300F39D851","order_id":1,"type_id":6,"title":"Section","source":{"title":"Visit Windows"}},{"id":1054724,"guid":"BFFA59DA80C548D7ABC344D1DA1604F7","order_id":1,"type_id":1,"title":"description","source":{"description":"<div class = \"text-blocks\"><div class = \"text-block\"><span style = \"font-weight:bold;\">Scheduled Visits<\/span><\/div><div class = \"text-block\">All scheduled study visits in Appendix 1 must occur within the time limits specified below. Visits that occur outside of the specified windows will be considered protocol deviations.<\/div><div class = \"text-block\"><ul style = \"list-style-type:disc;\"><li style = \"counter-reset:ol0;list-style-type:disc;\"><span style = \"font-weight:bold;\">Visit -1<\/span><span>         <\/span><span style = \"font-weight:bold;\">Up to<\/span><span> 2-4 weeks before visit 0<\/span><\/li><li style = \"counter-reset:ol0;list-style-type:disc;\"><span style = \"font-weight:bold;\">Visit 0<\/span><span>          No window<\/span><\/li><li style = \"counter-reset:ol0;list-style-type:disc;\"><span style = \"font-weight:bold;\">Visit 1<\/span><span>          (\u00b1 3 days)<\/span><\/li><li style = \"counter-reset:ol0;list-style-type:disc;\"><span style = \"font-weight:bold;\">Visits 2-7<\/span><span>    <\/span><span style = \"font-weight:bold;\"> <\/span><span>(\u00b1 7 days)<\/span><\/li><li style = \"counter-reset:ol0;list-style-type:disc;\"><span style = \"font-weight:bold;\">Visits<\/span><span style = \"font-weight:bold;font-weight:bold;\"> <\/span><span style = \"font-weight:bold;\">8-11<\/span><span>   (\u00b1 14 days)<\/span><\/li><\/ul><\/div><\/div>"}},{"id":1054725,"guid":"3457972F6985455CB71FB0A5A7A0BC3D","order_id":2,"type_id":26,"title":"notes","source":{"id":0,"parent_id":0,"uri":"","title":"","body":"<div class = \"text-blocks\"><div style = \"text-align :; float : ;\"><img style = \"\" src = \"https:\/\/s3.amazonaws.com\/protocols-files\/files\/dtazbixhp.jpg\" \/><\/div><div style = \"text-align :; float : ;\"><img style = \"\" src = \"https:\/\/s3.amazonaws.com\/protocols-files\/files\/dtbgbixhp.jpg\" \/><\/div><div style = \"text-align :; float : ;\"><img style = \"\" src = \"https:\/\/s3.amazonaws.com\/protocols-files\/files\/dtbtbixhp.jpg\" \/><\/div><\/div>","created_on":0,"changed_on":0,"creator":{"name":" ","affiliation":null,"affiliations":[],"username":"","note":null,"link":null,"image":{"source":"","placeholder":""},"badges":[],"verified":0,"is_verified_user":false,"research_interests":null,"blocked_by_you":false,"blocked_you":false,"hide_following":false},"comments":[]}}],"cases":[],"data":null,"html":null,"section":null,"section_color":"#FFED92","section_duration":0,"critical":null,"critical_id":null,"duration":0}],"document":"","materials":[],"description":"<div class = \"text-blocks\"><div class = \"text-block\">This is Part 6 of \"Safety and Efficacy of Imatinib for Preserving Beta-Cell Function in New-Onset Type 1 Diabetes Mellitus\".<\/div><div class = \"text-block\">This clinical study is supported by JDRF. The aim of the collection is to determine whether imatinib will slow the progression of the autoimmune destruction of \u00df cells and lead to the preservation of C-peptide secretion in T1DM and to assess Diabetes-related objectives and safety of Imatinib in new-onset type 1 diabetes mellitus\".<\/div><\/div>","changed_on":1623449406}